NASDAQ:CAPR

Capricor Therapeutics (CAPR) Stock Price, News & Analysis

Capricor Therapeutics logo
$7.91 +0.38 (+5.03%)
As of 10:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Capricor Therapeutics Stock (NASDAQ:CAPR)

Advanced

Key Stats

Today's Range
$7.48
▼
$8.34
50-Day Range
$5.74
▼
$11.22
52-Week Range
$2.96
▼
$40.37
Volume
3.53 million shs
Average Volume
3.26 million shs
Market Capitalization
$459.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.09
Consensus Rating
Hold

Company Overview

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options.

The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness.

Capricor is also advancing an exosome-based technology platform for potential therapeutic applications. The company is headquartered in San Diego, California, and its chief executive officer is Linda Marbán.

AI Generated. May Contain Errors.

Capricor Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

CAPR MarketRank™: 
3.06624518966 of 5 stars

Capricor Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 306th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Capricor Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on no strong buy ratings, 5 buy ratings, 5 hold ratings, and 1 sell rating.

  • Upside Potential

    Capricor Therapeutics has a consensus price target of $30.09, representing about 299.6% upside from its current price of $7.53.

  • Amount of Analyst Coverage

    Capricor Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Capricor Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Capricor Therapeutics are expected to grow in the coming year, from ($2.39) to ($1.27) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Capricor Therapeutics is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Capricor Therapeutics is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Capricor Therapeutics has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    35.55% of the float of Capricor Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Capricor Therapeutics has a short interest ratio ("days to cover") of 7.38.
  • Change versus previous month

    Short interest in Capricor Therapeutics has recently decreased by 5.52%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Capricor Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Capricor Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Capricor Therapeutics has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Capricor Therapeutics this week, compared to 9 articles on an average week.
  • Search Interest

    Only 19 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    9.20% of the stock of Capricor Therapeutics is held by insiders.

  • Percentage Held by Institutions

    21.68% of the stock of Capricor Therapeutics is held by institutions.

  • Read more about Capricor Therapeutics' insider trading history.
Receive CAPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CAPR Stock News Headlines

Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
Capricor Stock Rises: What's Going On?
HC Wainwright Has Pessimistic View of CAPR FY2026 Earnings
Capricor Therapeutics (NASDAQ:CAPR) Upgraded at JonesTrading
See More Headlines

CAPR Stock Analysis - Frequently Asked Questions

Capricor Therapeutics' stock was trading at $28.86 at the beginning of 2026. Since then, CAPR shares have decreased by 73.9% and is now trading at $7.53.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) posted its quarterly earnings data on Tuesday, November, 10th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.29.
Read the conference call transcript
.

Capricor Therapeutics' top institutional investors include State Street Corp (5.19%), RA Capital Management L.P. (5.18%), Soleus Capital Management L.P. (1.20%) and Goldman Sachs Group Inc. (1.20%). Insiders that own company stock include Shinyaku Co Ltd Nippon, Anthony Bergmann and Karimah Es Sabar.
View institutional ownership trends
.

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), NIO (NIO), Tesla (TSLA), Alibaba Group (BABA), Vaxart (VXRT) and Micron Technology (MU).

Company Calendar

Last Earnings
11/10/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CAPR
CIK
1133869
Employees
231
Year Founded
2005

Price Target and Rating

High Price Target
$60.00
Low Price Target
$2.00
Potential Upside/Downside
+291.7%
Consensus Rating
Hold
Rating Score (0-4)
2.36
Research Coverage
11 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$105.04 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-56.71%
Return on Assets
-42.71%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.77
Quick Ratio
6.77

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.61 per share
Price / Book
2.13

Miscellaneous

Outstanding Shares
58,142,000
Free Float
52,793,000
Market Cap
$446.70 million
Optionable
Optionable
Beta
0.80

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:CAPR) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners